EMA Authorised: Vemlidy (tenofovir alafenamide fumarate) — Gilead Sciences Ireland UC

View source ↗

Summary

The European Medicines Agency authorised Vemlidy (tenofovir alafenamide fumarate) for the treatment of hepatitis B. The decision date was 26 May 2023, and Gilea…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis B

Drugs mentioned

• Vemlidy (tenofovir alafenamide)

Snippet

Status: Authorised. Therapeutic area: Hepatitis B. MAH: Gilead Sciences Ireland UC. Decision date: 26/05/2023